NCT00116649View on ClinicalTrials.gov

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

PHASE4CompletedINTERVENTIONAL
Enrollment

551

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Keratosis
Interventions
DRUG

imiquimod cream

imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles

Trial Locations (32)

10021

New York

19031

Flourtown

22191

Woodbridge

27106

Winston-Salem

27262

High Point

27612

Raleigh

33021

Hollywood

33134

Coral Gables

33175

Miami

33401

West Palm Beach

46256

Indianapolis

53207

Milwaukee

55318

Chaska

60005

Arlington Heights

70006

Metairie

76011

Arlington

78229

San Antonio

80210

Denver

85044

Phoenix

89014

Henderson

89052

Henderson

89509

Reno

89521

Reno

90045

Los Angeles

90404

Santa Monica

91436

Encino

92117

San Diego

92506

Riverside

97210

Portland

99204

Spokane

06052

New Britain

02118

Boston

Sponsors
All Listed Sponsors
lead

Graceway Pharmaceuticals, LLC

INDUSTRY